This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Behavioural Health Remove Marketing Remove Regulation Related Topics
Pharma Companies Pharmacy Licensing FDA Approval Life Science Clinical Trials Medicine Trials Development Research More Related Topics >
article thumbnail

Pear extends digital therapeutics partnership with Spero

pharmaphorum

JANUARY 5, 2023

The deal centres on reSET and reSET-O, Pear’s cognitive behavioural therapy (CBT) based programmes, for people living with substance and opioid use disorders, respectively, which have been approved by the FDA as an adjunct to outpatient treatment. Pear secured approval for reSET-O in the following year.

Behavioural Health 52
Behavioural Health FDA Approval Licensing Licensing 52
article thumbnail

What we’re expecting in 2021, and beyond…

pharmaphorum

JANUARY 26, 2021

There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Consolidation of digital health platforms.

Clinical Trials 141
Clinical Trials Clinical Trials Sales Life Science 141
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024